These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38469242)

  • 61. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination of [
    Kim J; Lee S; Kim D; Kim HJ; Oh KT; Kim SJ; Choi YD; Giesel FL; Kopka K; Hoepping A; Lee M; Yun M
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1763-1772. PubMed ID: 38200396
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical parameters and nomograms for predicting lymph node metastasis detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
    Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT.
    Mihatsch PW; Beissert M; Pomper MG; Bley TA; Seitz AK; Kübler H; Buck AK; Rowe SP; Serfling SE; Hartrampf PE; Werner RA
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053434
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical insignificance of [
    Arnfield EG; Thomas PA; Roberts MJ; Pelecanos AM; Ramsay SC; Lin CY; Latter MJ; Garcia PL; Pattison DA
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4495-4507. PubMed ID: 34136957
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma.
    Udovicich C; Callahan J; Bressel M; Ong WL; Perera M; Tran B; Azad A; Haran S; Moon D; Chander S; Shaw M; Eapen R; Goad J; Lawrentschuk N; Murphy DG; Hofman M; Siva S
    Eur Urol Open Sci; 2022 Oct; 44():60-68. PubMed ID: 36185587
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 71. SUVmax/ADC Ratio as a Molecular Imaging Biomarker for Diagnosis of Biopsy-Naïve Primary Prostate Cancer.
    Chinnappan S; Chandra P; Kumar JS; Chandran G; Nath S
    Indian J Nucl Med; 2021; 36(4):377-384. PubMed ID: 35125755
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Standardised Uptake Value in Organ Confined Prostate Cancer in 68-Ga- Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography Scan and its Correlation with Prostate Specific Antigen Level and Gleason Score.
    Ali H; Rashid-Ul-Amin S; Hai A
    J Cancer Allied Spec; 2023; 9(2):529. PubMed ID: 37575209
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Initial Experience with Volumetric
    Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
    J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthesis, preclinical evaluation, and first-in-human study of Al
    Wu Y; Zhang X; Zhou H; Xu B; Tian J; Sun S; Zhang J
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2774-2785. PubMed ID: 35396969
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer.
    Luining WI; Hagens MJ; Meijer D; Ringia JB; de Weijer T; Bektas HO; Ettema RH; Knol RJJ; Roeleveld TA; Srbljin S; Weltings S; Koppes JCC; van Moorselaar RJA; van Leeuwen PJ; Oprea-Lager DE; Vis AN
    Eur Urol Open Sci; 2024 Jan; 59():55-62. PubMed ID: 38298765
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
    Schmidkonz C; Götz TI; Atzinger A; Ritt P; Prante O; Kuwert T; Bäuerle T; Goebell P; Cordes M
    Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist.
    Wang L; Yu F; Yang L; Zang S; Xue H; Yin X; Guo H; Sun H; Wang F
    Medicine (Baltimore); 2020 Sep; 99(36):e20755. PubMed ID: 32898989
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of histopathological and biochemical parameters for predicting metastatic disease on
    Aydos U; Çetin S; Akdemir ÜÖ; Budak FÇ; Ateş SG; Koparal MY; Gönül İI; Gülbahar Ö; Sözen S; Atay LÖ
    Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
    Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with
    Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP
    Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.